| 產(chǎn)品編號(hào) | BIO0998SM |
| 英文名稱 | Anti-DLL4 & VEGF Reference Antibody (Navicixizumab Biosimilar) |
| 別 名 | DLL4 & VEGF; Navicixizumab |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 146.17kDa |
| 性 狀 | Lyophilized |
| 亞 型 | IgG-like |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
To evaluate the neutralizing activity of Navicixizumab against VEGF. Co-incubation of Navicixizumab with VEGF protein, then with the addition of VEGF-NF-AT-HEK293 cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Navicixizumab can neutralize VEGF-165, and the IC50 was 7.957 nM.
Navicixizumab bound to huDLL4-FL-HEK293 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Navicixizumab bound to huDLL4-FL-HEK293 cells, and the EC50 was 4.603 nM.
Navicixizumab bound to VEGFA protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Navicixizumab bound to huVEGFA-His, and the EC50 was 0.020 nM.
Navicixizumab bound to DLL4 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Navicixizumab bound to huDLL4-His, and the EC50 was 0.033 nM.
The purity of Anti-DLL4 & VEGF Reference Antibody (Navicixizumab) is 97.99%, determined by SEC-HPLC.
Anti-DLL4 & VEGF Reference Antibody (Navicixizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
